chartexchange

Silexion Doses First Patient In Phase 2/3 SIL204 Trial For Pancreatic Cancer

RTTNews | Sep 30, 2026 9:16 AM EDT


(RTTNews) - Wednesday, Silexion Therapeutics (SLXN) said the first patient has been dosed in its global Phase 2/3 trial evaluating SIL204 in patients with locally advanced pancreatic cancer (LAPC).

Read original article